An economic evaluation of first-line cryoballoon ablation versus antiarrhythmic drug therapy for the treatment of paroxysmal atrial fibrillation from a German healthcare payer perspective
Initial rhythm control with cryoballoon ablation in symptomatic PAF is a cost-effective treatment option in a German healthcare setting.
Authors
- Stuart Mealing (ORCID: https://orcid.org/0000-0002-2564-1440)
- Emily Mitchell (ORCID: https://orcid.org/0000-0003-0379-3790)
- Eleni Ismyrloglou
- Malte Kuniss (ORCID: https://orcid.org/0000-0002-1593-9657)
- Joe W. E. Moss (ORCID: https://orcid.org/0000-0002-1866-9752)
- Tom Bromilow
- Florian Straube (ORCID: https://orcid.org/0000-0002-4491-5224)
- Alicia Sale (ORCID: https://orcid.org/0009-0003-3394-5246)
- Gian‐Battista Chierchia (ORCID: https://orcid.org/0000-0003-2967-1345)
- Oussama M. Wazni (ORCID: https://orcid.org/0000-0001-7115-7716)
- Jason G. Andrade (ORCID: https://orcid.org/0000-0002-8493-5123)
- Lucy Hillcoat
- Lukas Schwegmann
- Andreas Goette
Institutions
- Cleveland Clinic (US)
- Vrije Universiteit Brussel (BE)
- University of British Columbia (CA)
- Leeds and York Partnership NHS Foundation Trust (GB)
- München Klinik Bogenhausen (DE)
- Medtronic (United States) (US)
- Universitair Ziekenhuis Brussel (BE)
- Kerckhoff Klinik (DE)
- St. Vincenz-Krankenhaus Limburg (DE)
- Medtronic (Germany) (DE)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s12913-024-11967-0
- Citations
- 2
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.80